150 related articles for article (PubMed ID: 25082313)
1. [Malignant lymphoma in the central nervous system: overview].
Namekawa M
Brain Nerve; 2014 Aug; 66(8):907-16. PubMed ID: 25082313
[TBL] [Abstract][Full Text] [Related]
2. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
Schlegel U; Jürgens A; Pels H
Neurology; 2006 Apr; 66(8):1287; author reply 1287. PubMed ID: 16636266
[No Abstract] [Full Text] [Related]
3. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
Zhuang L; Lai J; Chen K; Ding T; Yuan Y; Ma Y; Kang H; Lin Z; Fan N; Ma J; Zeng Q; Xu X; Wang Q; Chen B
Oncol Rep; 2019 Jan; 41(1):397-404. PubMed ID: 30320386
[TBL] [Abstract][Full Text] [Related]
4. [Malignant Lymphoma of the Brain, and Dementia].
Mizutani S; Mizutani T
Brain Nerve; 2016 Apr; 68(4):383-90. PubMed ID: 27056856
[TBL] [Abstract][Full Text] [Related]
5. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
Küker W; Nägele T; Thiel E; Weller M; Herrlinger U
Neurology; 2005 Oct; 65(7):1129-31. PubMed ID: 16217075
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.
Kiewe P; Loddenkemper C; Anagnostopoulos I; Reinwald M; Thiel E; Korfel A
Neuro Oncol; 2007 Apr; 9(2):96-102. PubMed ID: 17301290
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma.
Abrey LE
Curr Opin Neurol; 2009 Dec; 22(6):675-80. PubMed ID: 19741527
[TBL] [Abstract][Full Text] [Related]
8. Imaging of primary central nervous system lymphoma.
Tang YZ; Booth TC; Bhogal P; Malhotra A; Wilhelm T
Clin Radiol; 2011 Aug; 66(8):768-77. PubMed ID: 21513925
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
10. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma: biological aspects and controversies in management.
Bessell EM; Hoang-Xuan K; Ferreri AJ; Reni M
Eur J Cancer; 2007 May; 43(7):1141-52. PubMed ID: 17433666
[TBL] [Abstract][Full Text] [Related]
12. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
Karantanis D; O'Neill BP; Subramaniam RM; Peller PJ; Witte RJ; Mullan BP; Wiseman GA
Clin Nucl Med; 2007 Apr; 32(4):271-4. PubMed ID: 17413571
[TBL] [Abstract][Full Text] [Related]
13. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
14. Primary central nervous system lymphoma: an update.
Soussain C; Hoang-Xuan K
Curr Opin Oncol; 2009 Nov; 21(6):550-8. PubMed ID: 19684518
[TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for central nervous system lymphomas in immunocompetent patients.
Jahnke K; Thiel E
Expert Rev Neurother; 2009 Oct; 9(10):1497-509. PubMed ID: 19831839
[TBL] [Abstract][Full Text] [Related]
17. Recurrent or refractory primary central nervous lymphoma: therapeutic considerations.
Dahiya S; Murphy ES; Chao ST; Stevens GH; Peereboom DM; Ahluwalia MS
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1109-19. PubMed ID: 24053208
[TBL] [Abstract][Full Text] [Related]
18. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
